HRTX | tickerfilter.com

Fundamental analysis

24%

Profitability 25%

Dept financing 7%

Liquidity 66%

Performance 16%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0 0%

1 Month

38.60%

3 Months

-16.40%

6 Months

-48.20%

1 Year

-11.73%

2 Year

-38.52%

Key data

Stock price

$1.60

P/E Ratio

0.00

DAY RANGE

$1.18 - $1.60

EPS

$0.00

52 WEEK RANGE

$1.10 - $3.93

52 WEEK CHANGE

-$5.39

MARKET CAP

292.719 M

YIELD

N/A

SHARES OUTSTANDING

151.668 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/11/2024

BETA

2.03

PUBLIC FLOAT

AVERAGE 10 VOLUME

$2,021,612

AVERAGE 30 VOLUME

$5,919,426

Company detail

CEO: Barry D. Quart
Region: US
Website: herontx.com
Employees: 300
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Heron Therapeutics, Inc. engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy.

HRTX - HERON THERAPEUTICS, INC. /DE/